Abstract Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This …

The VMAT-2 inhibitors are utilized for the management of chorea associated with Huntington Disease (HD) and for the management of tardive dyskinesia (TD). Tetrabenazine, the first VMAT-2 inhibitor, …

Tetrabenazine, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, is licensed in the UK for the treatment of moderate to severe tardive dyskinesia. Benzodiazepines, amantadine, botulinum toxin, …

Oct 6, 2025 · Tardive dyskinesia (TD) is a medication-induced hyperkinetic movement disorder associated with the use of dopamine receptor-blocking agents, including first- and second-generation …

Dec 1, 2022 · In conclusion, tardive dyskinesia appears as a side effect that should be carefully monitored, especially in elderly patients, due to the use of antipsychotics. Although there is limited …

Jul 14, 2025 · Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and …

OBJECTIVE: To describe long-term experience with tetrabenazine (TBZ) in the treatment of tardive dyskinesias. BACKGROUND: Dopamine receptor blocking drugs, commonly used in the treatment of …

The following sections provide suggestions for self-care for those with tardive dyskinesia and tardive syndromes. Click on each section to find out more information.

Oct 2, 2017 · T reatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review Stanley N Caroff, Saurabh Aggarwal*,2 & Charles Yonan

Nov 7, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …